rdf:type |
|
lifeskim:mentions |
umls-concept:C0011854,
umls-concept:C0021641,
umls-concept:C0021658,
umls-concept:C0030705,
umls-concept:C0035173,
umls-concept:C0040808,
umls-concept:C0041703,
umls-concept:C0332173,
umls-concept:C0332307,
umls-concept:C0439064,
umls-concept:C0540110,
umls-concept:C0650607,
umls-concept:C0907402,
umls-concept:C1257890
|
pubmed:issue |
8
|
pubmed:dateCreated |
2000-11-13
|
pubmed:abstractText |
Insulin glargine (HOE 901, 21(A)-Gly-30(B)a-L-Arg-30(B)b-L-Arg human insulin) is a novel recombinant analog of human insulin with a shift in the isoelectric point producing a retarded absorption rate and an increased duration of action that closely mimics normal basal insulin secretion. It recently received approval from the Food and Drug Administration. The aim of this study was to evaluate 2 formulations of insulin glargine for safety and efficacy in the treatment of patients with type 1 diabetes.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0149-5992
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1137-42
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10937511-Adult,
pubmed-meshheading:10937511-Blood Glucose,
pubmed-meshheading:10937511-Circadian Rhythm,
pubmed-meshheading:10937511-Diabetes Mellitus, Type 1,
pubmed-meshheading:10937511-Double-Blind Method,
pubmed-meshheading:10937511-Drug Administration Schedule,
pubmed-meshheading:10937511-Fasting,
pubmed-meshheading:10937511-Female,
pubmed-meshheading:10937511-Humans,
pubmed-meshheading:10937511-Hypoglycemic Agents,
pubmed-meshheading:10937511-Injections, Subcutaneous,
pubmed-meshheading:10937511-Insulin,
pubmed-meshheading:10937511-Insulin, Isophane,
pubmed-meshheading:10937511-Insulin, Long-Acting,
pubmed-meshheading:10937511-Male,
pubmed-meshheading:10937511-Time Factors
|
pubmed:year |
2000
|
pubmed:articleTitle |
Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
|
pubmed:affiliation |
Dallas Diabetes and Endocrine Center, Texas 75230, USA. juliorosenstock@dallasdiabetes.com
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|